AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11849412 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 51
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection episodes
Number of subjects: 51
Study 11849412 — intervention group
Group type: COMPARATOR
Intervention: No acute rejection episodes
Number of subjects: 51
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 51
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months
Number of subjects: 51
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months
Number of subjects: 51
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months
Number of subjects: 51
Study 10402079 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 30 mg ketoprofen plaster (n = 40)
Number of subjects: 100
Study 10402079 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple applications of 30 mg ketoprofen plaster for 5 days (n = 30)
Number of subjects: 100
Study 10402079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of 50 mg ketoprofen (n = 30)
Number of subjects: 100
Study 7594331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 30 mg once daily
Number of subjects: 20
Study 7594331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 30 mg twice daily
Number of subjects: 20
Study 7594331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole injection 15 mg twice daily
Number of subjects: 20
Study 7594331 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonist 20 mg twice daily
Number of subjects: 20
Study 2379945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (5-40 mmol/24 hours)
Number of subjects: 12
Study 2379945 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet (160-200 mmol/24 hours)
Number of subjects: 12
Study 31896035 — intervention group
Group type: EXPERIMENTAL
Intervention: Branching path simulation training
Number of subjects: 102
Study 31896035 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures (Control)
Number of subjects: 102
Study 28207546 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature water immersion (RWI)
Number of subjects: 53
Study 28207546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-water immersion (IWI)
Number of subjects: 53
Study 28207546 — intervention group
Group type: COMPARATOR
Intervention: No water immersion (Control)
Number of subjects: 53
Study 24413368 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 130
Study 24413368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23013440 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 1009
Study 23013440 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 1009
Study 22182865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intercostal nerve block (CINB) with 0.2% ropivacaine infusion
Number of subjects: 102
Study 22182865 — intervention group
Group type: COMPARATOR
Intervention: Historical control using epidural analgesia
Number of subjects: 102
Study 21092270 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA feeding prior to allergen sensitization and challenge
Number of subjects: 0
Study 21092270 — intervention group
Group type: COMPARATOR
Intervention: PBS feeding
Number of subjects: 0
Study 17603390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sampling at 7- to 14-day intervals
Number of subjects: 10000
Study 17603390 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall period of 48 hours
Number of subjects: 10000
Study 17603390 — intervention group
Group type: COMPARATOR
Intervention: Continuous surveillance
Number of subjects: 10000
Study 14759615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Number of subjects: 100
Study 14759615 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-EN (norethisterone enanthate 200 mg)
Number of subjects: 100
Study 14759615 — intervention group
Group type: COMPARATOR
Intervention: Both Cyclofem and NET-EN
Number of subjects: 100
Study 11772793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thoracic epidural analgesia (TEA) with bupivacaine and morphine solution, postoperative epidural PCA
Number of subjects: 69
Study 11772793 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thoracic epidural analgesia (TEA) with bolus dose
Number of subjects: 69
Study 11772793 — intervention group
Group type: COMPARATOR
Intervention: IV patient‐controlled analgesia (IV‐PCA) with morphine
Number of subjects: 69
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 60
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 60
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 60
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 60
Study 9690692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (group 1)
Number of subjects: 60
Study 9690692 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day (group 2)
Number of subjects: 60
Study 9690692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1 and group 2)
Number of subjects: 60
Study 7806092 — intervention group
Group type: EXPERIMENTAL
Intervention: Congo red positive patients (9 out of 62)
Number of subjects: 62
Study 7806092 — intervention group
Group type: COMPARATOR
Intervention: Congo red negative patients
Number of subjects: 62
Study 2668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine 400 mg daily
Number of subjects: 190
Study 2668978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 403395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with radiotherapy (5000 rads) and ICRF 159 (250 mg p.d.)
Number of subjects: 40
Study 403395 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (5000 rads)
Number of subjects: 40
Study 403395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with radiotherapy and ICRF 159
Number of subjects: 40
Study 30442024 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction Therapy for Adolescents (RRTA)
Number of subjects: 105
Study 30442024 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 105
Study 30442024 — intervention group
Group type: COMPARATOR
Intervention: Both RRTA and TAU
Number of subjects: 105
Study 28893464 — intervention group
Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane [BPU] dressing, sutureless securement device)
Number of subjects: 101
Study 28893464 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated securement dressings (ISDs)
Number of subjects: 101
Study 28893464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA) plus BPU dressing
Number of subjects: 101
Study 27136912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under high-fat breakfast conditions
Number of subjects: 0
Study 27136912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under low-fat breakfast conditions
Number of subjects: 0
Study 27136912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 100 mg under high-fat breakfast conditions
Number of subjects: 0
Study 27136912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg under fasted conditions
Number of subjects: 0
Study 27136912 — intervention group
Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 0
Study 23873570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with 125 µg OMP alone
Number of subjects: 0
Study 23873570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with OMP+NP
Number of subjects: 0
Study 23873570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with OMP only
Number of subjects: 0
Study 23873570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with or without NP
Number of subjects: 0
Study 23873570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous vaccination with 125 µg OMP alone and OMP+NP
Number of subjects: 0
Study 23873570 — intervention group
Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 0
Study 21735362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri‐Learn buffet (NLB)
Number of subjects: 134
Study 21735362 — intervention group
Group type: COMPARATOR
Intervention: Conventional counselling tools (pictures and tables)
Number of subjects: 134
Study 19371311 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion at 30 microg min(‐1)
Number of subjects: 0
Study 19371311 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion at 100 microg min(‐1)
Number of subjects: 0
Study 19371311 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion at 50 microg min(‐1)
Number of subjects: 0
Study 19371311 — intervention group
Group type: COMPARATOR
Intervention: Morphine with antihistamines pretreatment
Number of subjects: 0
Study 19371311 — intervention group
Group type: COMPARATOR
Intervention: Morphine with nitric oxide clamp
Number of subjects: 0
Study 19371311 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine alone
Number of subjects: 0
Study 16049190 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) study with a delayed naming task
Number of subjects: 0
Study 12631527 — intervention group
Group type: EXPERIMENTAL
Intervention: Spelling performance task (sub‐word‐level and lexical route)
Number of subjects: 23
Study 12631527 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal testing after 6-12 months
Number of subjects: 23
Study 10696747 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival mydricaine and topical diclofenac 0.1%
Number of subjects: 57
Study 10696747 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival mydricaine
Number of subjects: 57
Study 10696747 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac 0.1%
Number of subjects: 57
Study 9186240 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent negative variations (CNVs) recorded from subdural electrodes
Number of subjects: 14
Study 9186240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereitschaftspotentials (BPs) recorded from subdural electrodes
Number of subjects: 14
Study 9186240 — intervention group
Group type: EXPERIMENTAL
Intervention: Late CNVs
Number of subjects: 14
Study 9186240 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentials observed after S2
Number of subjects: 14
Study 8471328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) and Vindesine (VDS) with MER
Number of subjects: 103
Study 8471328 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) and Vindesine (VDS) without MER
Number of subjects: 103
Study 3492759 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim twice a day
Number of subjects: 74
Study 3492759 — intervention group
Group type: COMPARATOR
Intervention: 160 mg trimethoprim plus 800 mg sulphamethoxazole twice a day
Number of subjects: 74
Study 31981972 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional face‐to‐face teaching
Number of subjects: 296
Study 31981972 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐learning
Number of subjects: 296
Study 31981972 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 296
Study 29573143 — intervention group
Group type: EXPERIMENTAL
Intervention: Q/LAIV
Number of subjects: 1301
Study 29573143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1301
Study 27448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation cryoballoon
Number of subjects: 74
Study 27448816 — intervention group
Group type: COMPARATOR
Intervention: Second-generation cryoballoon
Number of subjects: 74
Study 27448816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 24945884 — intervention group
Group type: EXPERIMENTAL
Intervention: Health communication intervention (face-to-face education and booster call)
Number of subjects: 150
Study 24945884 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study 22732846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual ketorolac (10 mg 4 times daily)
Number of subjects: 47
Study 22732846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam (20 mg once daily)
Number of subjects: 47
Study 20683319 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 60
Study 20683319 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide
Number of subjects: 60
Study 19020158 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with ropivacaine
Number of subjects: 50
Study 19020158 — intervention group
Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 50
Study 15932840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F(2alpha) + ATP (0.45 nmol/min, intravenously)
Number of subjects: 34
Study 15932840 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F(2alpha) (7.5 mug/min, intravenously)
Number of subjects: 34
Study 12074779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate risk model using total PSA, percentage of free PSA, prostate volume, and DRE findings
Number of subjects: 758
Study 12074779 — intervention group
Group type: COMPARATOR
Intervention: Percentage of free PSA
Number of subjects: 758
Study 12074779 — intervention group
Group type: COMPARATOR
Intervention: Total PSA, prostate volume, and DRE findings
Number of subjects: 758
Study 12074779 — intervention group
Group type: COMPARATOR
Intervention: Age and family history of prostate cancer
Number of subjects: 758
Study 9523857 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking water with less than 1.57 micromol/l (<0.1 mg/l)
Number of subjects: 128
Study 9523857 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking water with 31.48 micromol/l (2 mg/l) of copper
Number of subjects: 128
Study 8590557 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 3300 lux of cool-white fluorescent light for either 1 h or 15 min in the morning for 2 weeks (Intervention)
Number of subjects: 18
Study 2568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine (7.5 mg)
Number of subjects: 12
Study 2568660 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 12
Study 2568660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 798330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone therapy at the time of kidney transplantation
Number of subjects: 45
Study 798330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 31448392 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections (triamcinolone in 2% xylocaine)
Number of subjects: 80
Study 31448392 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 80
Study 29272063 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (assessed by hypo-score)
Number of subjects: 1441
Study 29272063 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (T2)
Number of subjects: 1441
Study 29272063 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemia (T3)
Number of subjects: 1441
Study 27424013 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (3 days per week for 3 months, 36 sessions total, 45 minutes each session)
Number of subjects: 0
Study 27424013 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 0
Study 23730848 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-RT
Number of subjects: 19
Study 23730848 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 19
Study 22543001 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exposure to training
Number of subjects: 39
Study 22543001 — intervention group
Group type: COMPARATOR
Intervention: Delayed exposure to training
Number of subjects: 39
Study 20591206 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-long-chain inulin (VLCI) 10 g/d
Number of subjects: 32
Study 20591206 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo) 10 g/d
Number of subjects: 32
Study 18019992 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral component placed parallel to the epicondylar axis (computer assisted group)
Number of subjects: 60
Study 18019992 — intervention group
Group type: COMPARATOR
Intervention: Femoral component placed in 3 degrees external rotation to the posterior condylar axis (control group)
Number of subjects: 60
Study 16214044 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-sponsored RCTs
Number of subjects: 655
Study 12153966 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention plus Atrovent inhaler (SI-A) group, received ipratropium bromide
Number of subjects: 149
Study 12153966 — intervention group
Group type: COMPARATOR
Intervention: Smoking intervention plus placebo inhaler (SI-P) group, received placebo
Number of subjects: 149
Study 12153966 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants considered with smoking status as a time-dependent covariate
Number of subjects: 149
Study 10320256 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cerebral perfusion (RCP)
Number of subjects: 5
Study 10320256 — intervention group
Group type: COMPARATOR
Intervention: Selective cerebral perfusion (SCP)
Number of subjects: 5
Study 8578060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on therapy; different dosages not specified.
Number of subjects: 0
Study 8578060 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 0
Study 1924663 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 42
Study 1924663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6123647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (assumed benefit for rapid growth stratum)
Number of subjects: 164
Study 31762024 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant brown rice (IBR)
Number of subjects: 14
Study 31762024 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined maize ugali (RMU)
Number of subjects: 14
Study 31762024 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole maize ugali (WMU)
Number of subjects: 14
Study 31762024 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain pilaf (WGP)
Number of subjects: 14
Study 29229000 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered, computerized SBIRT intervention
Number of subjects: 208
Study 29229000 — intervention group
Group type: COMPARATOR
Intervention: Clinician-administered SBIRT intervention
Number of subjects: 208
Study 26486976 — intervention group
Group type: EXPERIMENTAL
Intervention: FACETS programme
Number of subjects: 72
Study 23963438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Number of subjects: 54
Study 23963438 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic training
Number of subjects: 54
Study 23963438 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 22176767 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30
Study 22176767 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 20672447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 5 mg
Number of subjects: 118
Study 20672447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg
Number of subjects: 118
Study 20672447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg
Number of subjects: 118
Study 20672447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 20672447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc (all doses)
Number of subjects: 118
Study 17933470 — intervention group
Group type: EXPERIMENTAL
Intervention: Public speaking stress
Number of subjects: 22
Study 17933470 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro beta-adrenergic stimulation of PBCs
Number of subjects: 22
Study 16244538 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + Gln placebo + diet
Number of subjects: 41
Study 16244538 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + Gln + diet
Number of subjects: 41
Study 16244538 — intervention group
Group type: COMPARATOR
Intervention: Gln + diet
Number of subjects: 41
Study 12323178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level dissection group
Number of subjects: 35
Study 12323178 — intervention group
Group type: COMPARATOR
Intervention: Low-level dissection group
Number of subjects: 35
Study 10546931 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of intravitreal TPA in buffered salt solution (BSS) 15 minutes before vitrectomy
Number of subjects: 56
Study 10546931 — intervention group
Group type: COMPARATOR
Intervention: BSS alone
Number of subjects: 56
Study 7477217 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32
Study 7477217 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32
Study 7477217 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32
Study 7477217 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg or 300 mg of oral lamivudine daily for 12 weeks
Number of subjects: 32
Study 7477217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 32
Study 2124651 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BCAA) administration postoperatively in gastrectomized rats and in humans after subtotal or total gastrectomy.
Number of subjects: 0